Barclays
RAPP icon

Barclays’s Rapport Therapeutics RAPP Stock Holding History

Barclays’s Portfolio RAPP Stock Details RAPP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$916K Buy
27,271
+12,277
+82% +$530K ﹤0.01% 3110
2026
Q2 		$625K Buy
14,994
+5,383
+56% +$198K ﹤0.01% 3093
2026
Q1 		$301K Sell
9,611
-42,869
-82% -$1.21M ﹤0.01% 3470
2025
Q4 		$1.59M Buy
52,480
+25,767
+96% +$713K ﹤0.01% 3095
2025
Q3 		$793K Sell
26,713
-44,395
-62% -$792K ﹤0.01% 3514
2025
Q2 		$808K Buy
71,108
+8,412
+13% +$89.3K ﹤0.01% 3477
2025
Q1 		$629K Buy
62,696
+44,199
+239% +$574K ﹤0.01% 3383
2024
Q4 		$328K Buy
18,497
+5,634
+44% +$125K ﹤0.01% 4068
2024
Q3 		$263K Buy
12,863
+3,463
+37% +$74.4K ﹤0.01% 4151
2024
Q2 		$219K Buy
+9,400
New +$218K ﹤0.01% 3531

Other funds holding RAPP

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Johnson & Johnson
Johnson & Johnson New Brunswick, New Jersey $762M AUM 69.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Candriam SCA
Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $118B AUM 40.52% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
ALPS Advisors
ALPS Advisors Denver, Colorado $21.8B AUM 17.58% 1-Year Est. Return

Barclays's RAPP Position: Q3 2026 in Review

Barclays increased its Rapport Therapeutics (RAPP) stake by 82% in Q3 2026, buying an estimated $530K and bringing the position to 27,271 shares worth $916K. The position accounts for ﹤0.01% of the portfolio, ranked #3110.

Barclays first reported a position in RAPP in Q2 2024 and has held it in 10 quarters since. The position peaked at $1.59M in Q4 2025. 67 funds tracked by Wall St. Rank hold RAPP as of Q3 2026.

  • Barclays held 27,271 shares of Rapport Therapeutics worth $916K as of Q3 2026.
  • Barclays bought 12,277 Rapport Therapeutics shares in Q3 2026, an estimated $530K.
  • Rapport Therapeutics made up ﹤0.01% of Barclays's portfolio in Q3 2026, its #3110 holding.
  • Barclays first reported a position in Rapport Therapeutics in Q2 2024 and has held it in 10 quarters since.
  • Barclays's Rapport Therapeutics position peaked at $1.59M in Q4 2025.
  • 67 funds tracked by Wall St. Rank held Rapport Therapeutics as of Q3 2026.

Based on Barclays's 13F filing for Q3 2026, filed 6 Nov 2026.